Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Menopause01:28

Menopause

165
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
165
Obesity01:24

Obesity

503
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
503
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

389
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
389
Signs of Puberty01:27

Signs of Puberty

350
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
350
Bone Disorders01:29

Bone Disorders

3.5K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
3.5K
Stress Prevention and Stress Management Techniques IV01:26

Stress Prevention and Stress Management Techniques IV

29
Stress often leads to unhealthy habits like smoking, excessive drinking, and overeating, which offer short-term relief but ultimately increase long-term health risks. These behaviors create a cycle that temporarily lowers stress levels but can result in severe long-term health consequences. Breaking these habits is essential to reduce the risk of chronic diseases and improve overall well-being. Three primary changes that support better health include quitting smoking, reducing alcohol intake,...
29

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidisciplinary Management of Women Suffering from Migraine: Rationale, Design and Results of a National Delphi Consensus.

Healthcare (Basel, Switzerland)·2026
Same author

Effect of patient and partner preconceptional nutraceutical supplementation on the onset of natural pregnancy: a retrospective study.

Revista da Associacao Medica Brasileira (1992)·2026
Same author

Health Outcome Determinants of Human Papillomavirus Vaccination in Adult Women in Spain.

Vaccines·2026
Same author

Estradiol loss, the "estrobolome," and midlife symptoms: what the gut microbiome adds to menopause care.

Menopause (New York, N.Y.)·2026
Same author

Health-Related Quality of Life in Menopausal Women with Cancer: Results from the CALCAN Study.

Cancers·2026
Same author

Multidimensional health evaluation in mid-aged women: cross-sectional study protocol for a future-implementable program.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2026

Related Experiment Video

Updated: Jul 3, 2025

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

15.5K

Obesity and menopause.

Santiago Palacios1, Peter Chedraui2, Rafael Sánchez-Borrego3

  • 1Palacios's Clinic for Women's Health, Madrid, Spain.

Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology
|February 12, 2024
PubMed
Summary

Obesity is a complex disease, not a lack of willpower. For menopausal women, obesity worsens health, but certain hormone therapies may be safe, depending on type and delivery.

Keywords:
Obesityfracture riskhormone therapymenopausevasomotor symptoms

More Related Videos

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

390

Related Experiment Videos

Last Updated: Jul 3, 2025

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

15.5K
An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

12.2K
An Acupoint Catgut-embedding Therapy for Treating Obesity
04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

390

Area of Science:

  • Reproductive endocrinology and metabolism
  • Women's health and aging

Background:

  • Obesity is a multifactorial, chronic disease, not a matter of willpower.
  • Menopause involves hormonal and body composition changes, increasing visceral adiposity and health risks.
  • Obesity impacts reproductive hormones and is linked to menstrual irregularities and exacerbated menopausal symptoms.

Purpose of the Study:

  • To clarify the complex interplay between obesity, aging, menopause, and hormone levels.
  • To evaluate the risks of menopause hormone therapy (MHT) in women with obesity.

Main Methods:

  • Review of existing literature on obesity, menopause, and hormone therapy.
  • Analysis of risk factors for thromboembolic disease in relation to MHT in obese women.

Main Results:

  • Obesity exacerbates cardiometabolic, mechanical, and mental health issues during menopause.
  • Obesity is associated with altered menstrual cycles, hot flashes, sleep disturbances, pain, and reduced quality of life.
  • Transdermal estrogen-only or combined MHT does not elevate thrombotic risk in women with obesity.

Conclusions:

  • Obesity significantly impacts women's health during midlife and menopause.
  • The risk of thromboembolic events with MHT in obese women is dependent on the MHT's type and route of administration.
  • Transdermal MHT offers a safer alternative for managing menopausal symptoms in women with obesity.